Six Dimensional Evaluation for Myopia Prevention and Control
Jie Xu,Liang Xu
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical
University, Beijing Ophthalmology and Visual Science Key Lab, Beijing 100005, China
In 2017, the Chinese government has announced that myopia is the first irreversible blindness in Chinese, and it is based on the eye study in Beijing and Handan. Medical science is entering the era of precision medicine, big data and artificial intelligence. Multi-dimensional, quantitative and standardized measurement of myopia is the basis for the realization of artificial intelligence. The six dimensional evaluation of myopia control is heredity, diopter, increased nearwork, peripapillary atrophy, pathological myopia degree, intervention degree. ①Heredity: mainly evaluate the susceptibility of students to myopia;②Diopter: mainly record the development rate of myopia per year; ③Increased nearwork: using wearable instrument for monitoring; ④Monitoring the change of peripapillary atrophy; ⑤The level of chorioretinal atrophy: refer to Ohno-Matsui's grade; ⑥The level of intervention: it is referenced in the meta-analysis of international myopia intervention clinical trials. In order to prevent of pathological myopia, it should monitor the changes of the peripapillary atrophy in early state. Long-term monitoring of the fundus image from high myopia can see the relationship between the peripapillary atrophy and the chorioretinal atrophy.
徐捷,徐亮. 近视防控的六维度评估及防控模式[J]. 中华眼视光学与视觉科学杂志, 2018, 20(3): 129-132.
Jie Xu,Liang Xu. Six Dimensional Evaluation for Myopia Prevention and Control. Chinese Journal of Optometry Ophthalmology and Visual science, 2018, 20(3): 129-132. DOI: 10.3760/cma.j.issn.1674-845X.2018.03.001
Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health, 2013, 1(6): e339-e349.
[2]
Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based syste matic review.Am J Ophthalmol, 2014, 157(1): 9-25.e12. DOI: 10.1016/j.ajo.2013.08.010.
[3]
Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology, 2006, 113(7): 1134.e1-11. DOI: 10.1016/j.ophtha.2006.01.035.
[4]
Liang YB, Friedman DS, Wong TY, et al. Prevalence and causes of low vision and blindness in a rural chinese adult population:the Handan Eye Study. Ophthalmology, 2008, 115(11): 1965-1972. DOI: 10.1016/j.ophtha.2008.05.030.
[5]
Jonas JB, Xu L, Wei WB, et al. Myopia in China: a population-based cross-sectional, histological, and experimental study. Lancet,2016, 388: S20. DOI: 10.1016/S0140-6736(16)31947-X.
[6]
Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Metaanalysis.Ophthalmology, 2016, 123(4): 697-708. DOI: 10.1016/j.ophtha.2015.11.010.
[7]
Ohno-Matsui K. What is the fundamental nature of pathologic myopia? Retina, 2017, 37(6): 1043-1048. DOI: 10.1097/IAE.0000000000001348.
[1]
Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health, 2013, 1(6): e339-e349.
[2]
Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based syste matic review.Am J Ophthalmol, 2014, 157(1): 9-25.e12. DOI: 10.1016/j.ajo.2013.08.010.
[3]
Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology, 2006, 113(7): 1134.e1-11. DOI: 10.1016/j.ophtha.2006.01.035.
[4]
Liang YB, Friedman DS, Wong TY, et al. Prevalence and causes of low vision and blindness in a rural chinese adult population:the Handan Eye Study. Ophthalmology, 2008, 115(11): 1965-1972. DOI: 10.1016/j.ophtha.2008.05.030.
[5]
Jonas JB, Xu L, Wei WB, et al. Myopia in China: a population-based cross-sectional, histological, and experimental study. Lancet,2016, 388: S20. DOI: 10.1016/S0140-6736(16)31947-X.
[6]
Huang J, Wen D, Wang Q, et al. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Metaanalysis.Ophthalmology, 2016, 123(4): 697-708. DOI: 10.1016/j.ophtha.2015.11.010.
[7]
Ohno-Matsui K. What is the fundamental nature of pathologic myopia? Retina, 2017, 37(6): 1043-1048. DOI: 10.1097/IAE.0000000000001348.
[8]
Ohno-Matsui K. Pathologic Myopia. Asia Pac J Ophthalmol (Phila), 2016, 5(6): 415-423.
[9]
Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol, 2015, 159(5): 877-883.e7.DOI: 10.1016/j.ajo.2015.01.022.
[10]
Jonas JB, Wang YX, Zhang Q, et al. Macular Bruch's membrane length and axial Length. The Beijing Eye Study. Plos One, 2015,10(8): e0136833. DOI: 10.1371/journal.pone.0136833.
[8]
Ohno-Matsui K. Pathologic Myopia. Asia Pac J Ophthalmol (Phila), 2016, 5(6): 415-423.
[9]
Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol, 2015, 159(5): 877-883.e7.DOI: 10.1016/j.ajo.2015.01.022.
[10]
Jonas JB, Wang YX, Zhang Q, et al. Macular Bruch's membrane length and axial Length. The Beijing Eye Study. Plos One, 2015,10(8): e0136833. DOI: 10.1371/journal.pone.0136833.
[11]
Jonas JB, Nguyen XN, Gusek GC, et al. Parapapillary chorioretinal atrophy in normal and glaucoma eyes. I. Morphometric data.Invest Ophthalmol Vis Sci , 1989, 30(5): 908-918.
[11]
Jonas JB, Nguyen XN, Gusek GC, et al. Parapapillary chorioretinal atrophy in normal and glaucoma eyes. I. Morphometric data.Invest Ophthalmol Vis Sci , 1989, 30(5): 908-918.
[12]
Jonas JB, Fernández MC, Naumann GO. Glaucomatous parapapillary atrophy. Occurrence and correlations. Arch Ophthalmol, 1992, 110(2): 214-222.
[12]
Jonas JB, Fernández MC, Naumann GO. Glaucomatous parapapillary atrophy. Occurrence and correlations. Arch Ophthalmol, 1992, 110(2): 214-222.
[13]
Sugiyama K, Tomita G, Kawase K, et al. Disc hemorrhage and peripapillary atrophy in apparently healthy subjects. Acta
[13]
Sugiyama K, Tomita G, Kawase K, et al. Disc hemorrhage and peripapillary atrophy in apparently healthy subjects. Acta
Ophthalmol Scand, 1999, 77(2): 139-142.
Ophthalmol Scand, 1999, 77(2): 139-142.
[14]
Hayakawa T, Sugiyama K, Tomita G, et al. Correlation of the peripapillary atrophy area with optic disc cupping and disc hemorrhage. J Glaucoma, 1998, 7(5): 306-311.
[15]
Guo Y, Wang YX, Xu L, et al. Five-year follow-up of parapapillary atrophy: the Beijing Eye Study. PLoS One, 2012,7(5): e32005. DOI: 10.1371/journal.pone.0032005.
[16]
Jonas JB, Jonas SB, Jonas RA, et al. Parapapillary atrophy:histological gamma zone and delta zone. PLoS One, 2012,7(10): e47237. DOI: 10.1371/journal.pone.0047237.
[14]
Hayakawa T, Sugiyama K, Tomita G, et al. Correlation of the peripapillary atrophy area with optic disc cupping and disc hemorrhage. J Glaucoma, 1998, 7(5): 306-311.
[15]
Guo Y, Wang YX, Xu L, et al. Five-year follow-up of parapapillary atrophy: the Beijing Eye Study. PLoS One, 2012,7(5): e32005. DOI: 10.1371/journal.pone.0032005.
[16]
Jonas JB, Jonas SB, Jonas RA, et al. Parapapillary atrophy:histological gamma zone and delta zone. PLoS One, 2012,7(10): e47237. DOI: 10.1371/journal.pone.0047237.
浙公网安备 33030202001892号